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The use of muscle relaxants in intensive care patients is
rapidly declining. The most important reason for this is the
apparent development of a nondepolarizing, relaxant-
induced neuropathy, which leads to difficulty in weaning
patients from artificial ventilation, among other problems
[1]. Some frequently used drugs, such as corticosteriods
and aminoglycoside antibiotics, contribute to this
neuropathy [2]. Therefore, nowadays relaxants are only
administered in the ICU for specific indications, such as
when decreased muscle tone is required, for treating
patients who fight the ventilator and in order to allow
permissive hypercapnia.
Relaxants are still needed frequently in surgical anaesthesia
to facilitate quick procedures such as endotracheal
intubation. The depolarizing muscle relaxant succinylcholine
is often used for this purpose. Its ultra-short duration of
action renders rapid return of spontaneous breathing
possible if intubation fails. The situation in the ICU is
different, however. During anaesthesia, intubation and
artificial ventilation are only indicated to facilitate surgery by
ensuring an open airway. In the ICU these are absolute
indications, and rapid return of spontaneous ventilation is not
necessary, given that intubation is mainly indicated to start
artificial ventilation.
The potassium problem
Succinylcholine is known to have many unwanted effects. Its
mechanism of action (depolarization of muscle cell
membrane) results in the release of intracellular potassium by
upregulating acetylcholine receptors, especially outside the
motor endplate, and changing their characteristics [3–5].
Potassium release is already massively increased in a number
of circumstances and diseases that are frequently present in
ICU patients, including long-term immobilization, extensive
muscle trauma, many neuromuscular diseases, denervation of
muscles, burns, sepsis, encephalitis and acute renal failure.
Potassium release can be further augmented by acid–base
balance disturbances and by corticosteroids [6,7]. The
induced hyperkalaemia causes arrhythmias and sometimes
cardiac arrest. When such an arrest occurs it is difficult to
resuscitate the patient. In patients with myopathy or those
receiving long-term treatment with corticosteroids,
succinylcholine can contribute to rhabdomyolysis. It is likely
that cardiac arrest in such cases has an even higher mortality
rate than cardiac arrest in succinylcholine-induced
hyperkalaemia alone [8].
Unpredictable activity
In intensive care patients there is large variability in the
activity of plasma cholinesterase, an enzyme that metabolizes
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Abstract
Muscle relaxants in intensive care unit (ICU) patients are predominantly administered to facilitate
intubation. The adverse effect profile of succinylcholine is such that its use in the ICU must be
considered obsolete. Suitable alternatives are the intermediately long-acting nondepolarizing relaxants,
of which rocuronium is probably preferable.
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succinylcholine. For example, many drugs decrease plasma
cholinesterase activity, including ecothiopate, bambuterol,
corticosteroids, cytotoxics, anticonceptives and oestrogens.
Heart–lung machines that are used during cardiac surgery
induce a decrease in plasma cholinesterase activity, which
lasts for approximately 10 days [9]. Repeated plasma
exchange decreases plasma cholinesterase activity [10]. In
pregnancy (i.e. in patients with HELLP syndrome
[haemolysis, elevated liver enzymes, low platelets],
eclampsia, etc.), plasma cholinesterase activity is markedly
decreased, resulting in a prolonged succinylcholine effect
[11]. The same holds for patients with sepsis, malignancy,
burn trauma and liver disease [12]. In such patients there is a
wide variability in the neuromuscular blocking effect, onset
and duration of paralysis caused by succinylcholine [13,14].
Other side effects
Muscle hypertonia, myalgia, hypersalivation, elevated
intraocular and intracranial pressures, and induction of
malignant hyperthermia are also side effects of
succinylcholine [15]. Occasionally, harmful cardiovascular
effects also occur following succinylcholine administration,
caused by stimulation of nicotinic receptors in the autonomic
ganglia (sympathetic and parasympathetic) and of cardiac
muscarinic receptors [16]. Furthermore, succinylcholine
increases plasma noradrenaline (norepinephrine)
concentrations, resulting in cardiovascular effects. Finally, the
histamine-releasing properties of muscle relaxants are well
known, and succinylcholine has the strongest histamine-
releasing effect of all such agents.
Alternatives to succinylcholine
Given the profile described above, it is unlikely that many
authorities would approve succinylcholine for registration if it
were presented today as a new drug. Nondepolarizing muscle
relaxants do not have the deleterious effects connected with
depolarization. In order to be useful for facilitating endotracheal
intubation in the ICU, they must have an acceptable speed of
onset, have a relatively short to intermediate duration of action,
be noncumulative, and preferably should not have
cardiovascular side effects or induce histamine release.
Candidates to replace succinylcholine for intubation include
vecuronium, rocuronium, atracurium, cisatracurium and
mivacurium. The features of each drug are summarized in
Table 1. The onset of action of atracurium, cisatracurium and
vecuronium is rather long, and atracurium and cisatracurium
can release histamine. Rocuronium has an onset of action
similar to that of succinylcholine, and provides similar
intubation conditions 1 min after administration [17].
However, its duration of action is longer. The duration of
action of mivacurium is shorter, but it has a slower onset, the
intubation conditions are comparable only after 4–5 min, and
it has stronger histamine-releasing properties than does
rocuronium. Because mivacurium is metabolized by plasma
cholinesterase, the interindividual variability in effect is as
wide as with succinylcholine [18]. Many studies have shown
that rocuronium is a highly acceptable replacement for
succinylcholine in the ICU; therefore, in my opinion,
succinylcholine is obsolete.
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